Kenneth Baird, MD
Family Medicine · Carrollton, TXNPI 1194755256
Payments from drug & device makers
What this record shows
AbbVie accounts for 70.8% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2022 at $5,803 and has fallen 97.0% since, to $173 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 205 payments — averaging $40.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$6K
- Pfizer$396
- Lilly USA, LLC$232
- Abbott$186
- Eisai Inc.$143
- Cerapedics Inc.$141
- plus $1K from 31 others
Across 3 payments — averaging $49,653 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$149K
What the payments were for
- Speaking & faculty fees$5,00660%
- Food & beverage$3,36840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 82 | $5,927 |
| Pfizer | 19 | $396 |
| Lilly USA, LLC | 15 | $232 |
| Abbott | 3 | $186 |
| Eisai Inc. | 7 | $143 |
| Cerapedics Inc. | 1 | $141 |
| Antares Pharma, Inc. | 7 | $127 |
| AstraZeneca | 7 | $121 |
| GSK | 7 | $118 |
| Amgen | 6 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $95 |
| Merck | 4 | $69 |
| Amarin Pharma, Inc. | 3 | $58 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| Si-bone, Inc. | 2 | $52 |
| Novartis | 3 | $46 |
| Althera Pharmaceuticals LLC | 3 | $46 |
| Exact Sciences | 3 | $45 |
| Idorsia Pharmaceuticals US Inc | 3 | $41 |
| Novo Nordisk | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Bioventus LLC | 1 | $30 |
| Jazz Pharmaceuticals Inc. | 2 | $30 |
| Azurity Pharmaceuticals, Inc. | 2 | $29 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Therapeuticsmd, Inc. | 1 | $21 |
| Bausch Health US, LLC | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Exeltis, USA Inc. | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Adlon Therapeutics L.p. | 1 | $15 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Medtronic | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$158
- I-FACTOR PEPTIDE ENHANCED BONE GRAFT$141
- QULIPTA$125
- UBRELVY$125
- VRAYLAR$125
How this compares
$8,374 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 54 | $63,278 |
| EliquisApixaban | 48 | $58,336 |
| OxycontinOxycodone Hcl | 12 | $45,908 |
| JardianceEmpagliflozin | 26 | $25,596 |
| RybelsusSemaglutide | 17 | $22,765 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $19,334 |
| MounjaroTirzepatide | 16 | $18,216 |
| JanuviaSitagliptin Phosphate | 18 | $17,441 |
| MyrbetriqMirabegron | 17 | $11,863 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $6,762 |
| FarxigaDapagliflozin Propanediol | 11 | $6,298 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 153 | $4,527 |
| Liothyronine Sodium | 65 | $4,253 |
| Celecoxib | 50 | $4,060 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $3,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $38 | $86,04371 claims |
| PfizerEliquis | $396 | $58,33648 claims |
| Boehringer IngelheimJardiance | $11 | $25,59626 claims |
| MerckJanuvia, Janumet | $69 | $24,20330 claims |
| GSKTrelegy Ellipta | $118 | $19,33430 claims |
| Lilly USA, LLCMounjaro | $232 | $18,21616 claims |
| AstraZenecaFarxiga | $121 | $6,29811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Carrollton
- Rodney LindsayCarrollton$225K
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.